Skip to main content

Advertisement

SpringerLink
Log in

Methotrexate based chemotherapy and deferred radiotherapy for primary central nervous system lymphoma (PCNSL): single institution experience

  • Clinical–Patient Studies
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

In the following study, we present our experience in the treatment of PCNSL patients using a multi-step schedule combining chemotherapy and deferred radiotherapy. Patients were treated with two modified M-BACOD cycles and then differently according to radiological response For PR, SD and PD patients, chemotherapy was interrupted and radiotherapy initiated immediately (45 Gy Whole-brain RT). With CR patients, chemotherapy was continued with a combination of HMTX, VCZ, PCB and HD Ara-C up to a total of nine cycles. In 36 patients suitable for evaluation (2 patients had undergone tumour resection): 69.4% (25 of 36) had a complete response (CR), 19.4% (7 of 36) had a partial response(PR), 8.3% (3 of 36) had stable disease(SD), and 2.7% (one of 36) had progressive disease (PD). The PR, SD and PD patients were immediately treated by radiotherapy. In this cohort of patients, we observed 6 CR, 4 PR and 2 PD, respectively, following radiotherapy. At first relapse, a total of 16 CR patients were treated by radiotherapy for a total dose of 45 Gy. The OS was 42.1 months for the entire group of patients. In CR patients treated at the moment of recurrence by salvage radiotherapy, the TTP (time lasting from histological diagnosis until recurrence of disease before RT) was 28.3 months, with a 43.4% of disease free patients observed at 2 years. The median disease-free time observed after complete response to radiotherapy was 10.5 months. In 16 patients (34%), further progression of disease was observed following radiotherapy. Two patients developed extra-CNS disease in the breast and testis. When taking into account the patients with radiotherapy delayed at recurrence, the OS was 48 months and the survival rates were 70% and 60% at 2 years and 5 years, respectively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. DeAngelis LM, Wendy Seiferheld WS, Clifford Schold SC, Barbara Fisher B, Schultz CJ (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93–10. J Clin Oncol 20:4643–4648

    Article  PubMed  Google Scholar 

  2. Abrey LE, Yahalom J, DeAngelis LM (2000) Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18:3144–3150

    PubMed  CAS  Google Scholar 

  3. Ferreri AJ, Reni M, Pasini F, Calderoni A, Tirelli U, Pivnik A, Aondio GM, Ferrarese F, Gomez H, Ponzoni M, Borisch B, Berger F, Chassagne C, Iuzzolino P, Carbone A, Weis J, Pedrinis E, Motta T, Jouvet A, Barbui T, Cavalli F, Blay JY (2002) A multicenter study of treatment of primary CNS lymphoma. Neurology 58:1513–1520

    PubMed  CAS  Google Scholar 

  4. Harder H, Holtel H, Bromberg JE, Poortmans P, Haaxma-Reiche H, Kluin-Nelemans HC, Menten J, van den Bent MJ (2004) Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 62:544–547

    PubMed  CAS  Google Scholar 

  5. Correa DD, DeAngelis LM, Shi W, Thaler H, Glass A, Abrey LE (2004) Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62:548–555

    PubMed  CAS  Google Scholar 

  6. Fliessbach K, Helmstaedter C, Urbach H, Althaus A, Pels H, Linnebank M, Juergens A, Glasmacher A, Schmidt-Wolf IG, Klockgether T, Schlegel U (2005) Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 64:1184–1188

    PubMed  CAS  Google Scholar 

  7. Common Toxicity Criteria Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. DCTD, NCI, NIH, DHHS. March (1998)

  8. Bleecker ML, Bolla-Wilson K, Kawas C, Agnew J (1998) Age-specific norms for the Mini-Mental State Exam. Neurology 38:1565–1568

    Google Scholar 

  9. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277–1280

    PubMed  CAS  Google Scholar 

  10. Abrey LE, DeAngelis LM, Yahalom J (1998) Long term survival in primary CNS lymphoma. J Clin Oncol 16:859–863

    PubMed  CAS  Google Scholar 

  11. Neuwelt EA, Guastadisegni PE, Varallyay P, Doolittle ND (2005) Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. AJNR Am J Neuroradiol 26:258–265

    PubMed  Google Scholar 

  12. Batchelor TT, Kolak G, Ciordia R, Foster CS, Henson JW (2003) High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 9:711–715

    PubMed  CAS  Google Scholar 

  13. Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J, Frenay M, De Beule N, Delattre JY, Baron B (2003) European organization for research and treatment of cancer brain tumor group: chemotherapy alone as initial treatment for primary CNS Lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European organization for research and treatment of cancer brain tumor group. J Clin Oncol 21:2726–2731

    Article  PubMed  CAS  Google Scholar 

  14. Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Deckert M, Fimmers R, Helmstaedter C, Atasoy A, Klockgether T, Schlegel U (2003) Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21:4489–4495

    Article  PubMed  CAS  Google Scholar 

  15. Korfel A, Martus P, Nowrousian R et al (2003) The multicenter BMPD study for primary CNS lymphoma: long term results. Onkologie 26:37 (abstr 353)

    Article  CAS  Google Scholar 

  16. O’Brien P, Roos D, Pratt G, Liew K, Barton M, Poulsen M, Olver I, Trotter G (2000) Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 18:519–526

    PubMed  CAS  Google Scholar 

  17. Glass J, Gruber ML, Cher L, Hochberg FH (1994) Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 81:188–195

    Article  PubMed  CAS  Google Scholar 

  18. Reni M, Ferreri AJ, Guha-Thakurta N, Blay JY, Dell’Oro S, Biron P, Hochberg FH (2001) Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphoma treated with upfront high-dose methotrexate (>1 g/m2 HD-MTX). Int J Radiat Oncol Biol Phys 51:418–424

    Article  Google Scholar 

  19. Bessell EM, Graus F, Lopez-Guillermo A, Villa S, Verger E, Petit J, Holland I, Byrne P (2001) Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 20:231–236

    Article  Google Scholar 

  20. Reni M, Ferreri AJ (2004) Is withdrawal of consolidation radiotherapy an evidence-based strategy in primary central nervous system lymphomas? J Clin Oncol 22:1165–1167

    Article  PubMed  Google Scholar 

  21. De Vita VT (1983) The relationship between tumor mass and resistance to treatment of cancer. Cancer 51:1209–1220

    Article  Google Scholar 

  22. Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FD, Batchelor TT, Loeffler JS (2005) Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS Lymphoma. J Clin Oncol 23:1507–1513

    Article  PubMed  Google Scholar 

  23. Boiardi A, Silvani A, Pozzi A, Salmaggi A (1998) Radiotherapy at tumor recurrence in primary CNS lymphoma. Neurology 50:1934–1935

    PubMed  CAS  Google Scholar 

  24. Boiardi A, Silvani A, Pozzi A, Fariselli L, Broggi G, Salmaggi A (1999) Chemotherapy is effective as early treatment for primary central nervous system lymphoma. J Neurol 246:31–37

    Article  PubMed  CAS  Google Scholar 

  25. Abrey LE, Yahalom J, DeAngelis LM (2000) Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18:3144–3150

    PubMed  CAS  Google Scholar 

  26. DeAngelis LM, Yahalom J, Thaler HT, Kher U (1992) Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10:635–643

    PubMed  CAS  Google Scholar 

  27. Baumann MA, Ritch PS, Hande KR, Williams GA, Topping TM, Anderson T (1986) Treatment of intraocular lymphoma with high-doseAra-C. Cancer 57:1273–1275

    Article  PubMed  CAS  Google Scholar 

  28. Strauchen JA, Dalton J, Friedman AH (1989) Chemotherapy in the management of intraocular lymphoma. Cancer 63:1918–1921

    Article  PubMed  CAS  Google Scholar 

  29. Abrey LE, Tracy T. Batchelor TT, Ferreri AJM, Gospodarowicz M, Pulczynski EJ, Zucca E, Justine R. Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O’Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Franco Cavalli F (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS Lymphoma. J Clin Oncol 23:5034–5043

    Article  PubMed  Google Scholar 

  30. Fine HA (2002) Primary central nervous system lymphoma: time to ask the question. J Clin Oncol 20:4615–4617

    PubMed  Google Scholar 

  31. Mead GM, Bleehen NM, Gregor A, Bullimore J, Shirley D, Rampling RP, Trevor J, Glaser MG, Lantos P, Ironside JW, Moss TH, Brada M, Whaley JB, Stenning SP (2000) A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 89:1359–1370

    Article  PubMed  CAS  Google Scholar 

  32. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK,Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) European organisation for research and treatment of cancer brain tumor andradiotherapy groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 52:987–996

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuro-oncology, Istituto Nazionale Neurologico “Carlo Besta”, via Celoria, 11, Milan, 20133, Italy

    A. Silvani, A. Salmaggi, M. Eoli, E. Lamperti, A. Fiumani, P. Gaviani, A. Botturi & A. Boiardi

  2. Department of Neurosurgery, Istituto Nazionale Neurologico “Carlo Besta”, Milan, Italy

    G. Broggi & C. E. Marras

  3. Department of Radiotherapy Unit, Istituto Nazionale Neurologico “Carlo Besta”, Milan, Italy

    L. Fariselli & I. Milanesi

  4. Department of Neuroradiology, Istituto Nazionale Neurologico “Carlo Besta”, Milan, Italy

    A. Erbetta

  5. Department of Neurology and Neuropathology, Istituto Nazionale Neurologico “Carlo Besta”, Milan, Italy

    A. R. Giovagnoli & B. Pollo

Authors
  1. A. Silvani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Salmaggi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Eoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Lamperti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Broggi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. E. Marras
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L. Fariselli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. I. Milanesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Fiumani
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P. Gaviani
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A. Erbetta
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A. R. Giovagnoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. B. Pollo
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A. Botturi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. A. Boiardi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Silvani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Silvani, A., Salmaggi, A., Eoli, M. et al. Methotrexate based chemotherapy and deferred radiotherapy for primary central nervous system lymphoma (PCNSL): single institution experience. J Neurooncol 82, 273–279 (2007). https://doi.org/10.1007/s11060-006-9276-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-006-9276-0

Keywords

Search

Navigation